Abstract
The development of human immunodeficiency virus type 1 resistance to delavirdine (DLV) was studied in subjects receiving DLV monotherapy. Phenotypic resistance developed in 28 of 30 subjects within 8 weeks. K103N and Y181C, which confer nonnucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance, were the predominant reverse transcriptase mutations. P236L, which confers DLV resistance but hypersensitivity to other NNRTIs, developed in <10% of isolates.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase I
-
Clinical Trial, Phase II
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adult
-
Anti-HIV Agents / pharmacology*
-
Anti-HIV Agents / therapeutic use
-
Delavirdine / pharmacology*
-
Delavirdine / therapeutic use
-
Drug Resistance, Microbial / genetics
-
Female
-
HIV Infections / drug therapy
-
HIV Infections / virology*
-
HIV Reverse Transcriptase / genetics*
-
HIV-1 / drug effects*
-
HIV-1 / genetics
-
HIV-1 / isolation & purification
-
Humans
-
Male
-
Middle Aged
-
Molecular Sequence Data
-
Mutation*
-
RNA, Viral / blood
-
Reverse Transcriptase Inhibitors / pharmacology
-
Reverse Transcriptase Inhibitors / therapeutic use
Substances
-
Anti-HIV Agents
-
RNA, Viral
-
Reverse Transcriptase Inhibitors
-
Delavirdine
-
HIV Reverse Transcriptase
Associated data
-
GENBANK/AF090466
-
GENBANK/AF090467
-
GENBANK/AF090468
-
GENBANK/AF090469
-
GENBANK/AF090470
-
GENBANK/AF090471
-
GENBANK/AF090472
-
GENBANK/AF090473
-
GENBANK/AF090474
-
GENBANK/AF090475
-
GENBANK/AF090476
-
GENBANK/AF090477
-
GENBANK/AF090478
-
GENBANK/AF090479
-
GENBANK/AF090480
-
GENBANK/AF090481
-
GENBANK/AF090482
-
GENBANK/AF090483
-
GENBANK/AF090484
-
GENBANK/AF090485
-
GENBANK/AF090486
-
GENBANK/AF090487
-
GENBANK/AF090488
-
GENBANK/AF090489
-
GENBANK/AF090490
-
GENBANK/AF090491
-
GENBANK/AF090492
-
GENBANK/AF090493
-
GENBANK/AF090494
-
GENBANK/AF090495